Ireland
--:--IST
Recruiting Not applicable

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

NCT06606366 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-03-03
Last updated
2026-07-20

Condition(s) studied

Neoplasm Malignant

Investigational drug(s) / intervention(s)

Blood sample taken for the liquid biopsy

Blood sample taken for the liquid biopsy: 36 mL will be taken for the study.

Study summary

This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Over 18 years old. * Advanced-stage malignant solid tumor managed in a non-curative context. * Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion. * Patient able to read, write, and understand the French language. * Patient has read the information sheet and signed the informed consent. * Patient has social security coverage. Exclusion Criteria: * Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder. * Severe or uncontrolled systemic disease. * Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures. * Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8: * Pregnant women, women in labor, and breastfeeding mothers, * Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8, * Persons admitted to a healthcare or social institution for reasons other than research, * Adults unable to give their consent.

Primary outcome measure(s)

  • Sensitivity of liquid biopsy versus solid biopsy (gold standard) — 1 month
    The primary endpoind is the sensitivity of liquid biopsy versus solid biopsy as the gold standard for detecting genomic alterations evaluated in the studied gene panel. The panel will consist of 70 genes common to the PanoraMix panels (125 genes, FFPE) and Avida (104 genes, cpDNA).

Trial sites (1)

FacilityCityRegionStatus
Centre Antoine Lacassagne Nice France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06606366 on ClinicalTrials.gov ↗ ← All trials in France